The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcomes of the DIET study: A randomized controlled phase 2 trial of a high fiber diet intervention (HFDI) in patients with melanoma receiving immune checkpoint blockade (ICB).
 
Yufan Qiu
No Relationships to Disclose
 
Nazli Dizman
Stock and Other Ownership Interests - Several pharmaceutical companies (I)
Consulting or Advisory Role - Vivreon Biosciences
 
Yan Jiang
No Relationships to Disclose
 
Margaux Robert
No Relationships to Disclose
 
Rachel Farias
No Relationships to Disclose
 
Erma Levy
No Relationships to Disclose
 
Cindy Hwang
No Relationships to Disclose
 
Jian Wang
No Relationships to Disclose
 
Michael Wong
Consulting or Advisory Role - Castle Biosciences; Regeneron; Replimune
 
Sapna Patel
Honoraria - Cedars Sinai; Clinical Care Options; Clinical Education Alliance (Inst); Emory University; OncLive/MJH Life Sciences; Paradigm; University of Michigan; Vindico Medical Education (Inst)
Consulting or Advisory Role - Bristol Myers Squibb; Cardinal Health; Castle Biosciences; IDEAYA Biosciences; immatics; IO Biotech; MSD; Novartis; Obsidian Therapeutics; OncoSec; Pfizer; Replimune; TriSalus Life Sciences
Speakers' Bureau - BMS GmbH & Co. KG; MSD; Novartis
Research Funding - Bristol-Myers Squibb (Inst); Foghorn Therapeutics (Inst); IDEAYA Biosciences (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Castle Biosciences; InxMed; Melanoma Research Alliance (MRA); Melanoma Research Foundation; MSD; SITC/ACCC; SWOG; TriSalus Life Sciences
 
Alexandra Ikeguchi
Research Funding - BioNTech SE (Inst); Immunocore (Inst); Merck (Inst); Regeneron (Inst)
 
Isabella Oliva Glitz
Honoraria - Amgen
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Leal Therapeutics; Midatech Pharma; Novartis; Sintetica
Speakers' Bureau - Array BioPharma
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst)
 
Adi Diab
Honoraria - Cullinan Oncology (Inst); CureVac; CytomX Therapeutics; Genesis Therapeutics; Idera (Inst); Lytix Biopharma (Inst); Memgen; Nektar (Inst); Pfizer; Regeneron; Teva
Consulting or Advisory Role - Celgene; CureVac; CytomX Therapeutics; Idera; Memgen therapeutics; Nektar; Pfizer (Inst); Regeneron
Research Funding - Apexigen (Inst); Celgene (Inst); Cullinan Oncology (Inst); Cullinan Oncology (Inst); Idera (Inst); Lytix Biopharma (Inst); Lytix Biopharma (Inst); Nektar (Inst); Pfizer (Inst)
 
Hussein Tawbi
Consulting or Advisory Role - Boxer Capital; Bristol-Myers Squibb; Genentech/Roche; IO Biotech; Iovance Biotherapeutics; Jazz Pharmaceuticals; Medicenna; Merck; Novartis; Pfizer; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Dragonfly Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); RAPT Therapeutics (Inst); Regeneron (Inst)
 
Rodabe Amaria
Consulting or Advisory Role - Erasca, Inc; IO Biotech; KSQ Therapeutics; Obsidian Therapeutics; Replimune
Research Funding - Bristol-Myers Squibb (Inst); Erasc (Inst); Genentech (Inst); iovance Biotherapeutics (Inst); KSQ Therapeutics (Inst); Novartis (Inst); Obsidian Therapeutics (Inst); OnKure (Inst); Regeneron (Inst)
 
Michael Davies
Consulting or Advisory Role - ABM; Apexigen; Array BioPharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Iovance Biotherapeutics; NanoString Technologies; Novartis; Nurix; Pfizer; Replimune
Research Funding - ABM (Inst); AstraZeneca (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Lead Pharma (Inst); Merck (Inst); Myriad Genetics (Inst); Oncothyreon (Inst); Pfizer (Inst); Sanofi (Inst)
 
Nadim Ajami
Stock and Other Ownership Interests - Moderna Therapeutics
Research Funding - SNIPR BIOME
 
Jennifer Wargo
Stock and Other Ownership Interests - Micronoma
Honoraria - Daiichi Sankyo/UCB Japan; EverImmune; Gustave Roussy Cancer Center; OSE Immunotherapeutics; Peerview
Consulting or Advisory Role - Daiichi Sankyo/UCB Japan; EverImmune; Gustave Roussy Cancer Center; OSE Immunotherapeutics; Peerview
Patents, Royalties, Other Intellectual Property - Patent submitted regarding the role of the microbiome in response to immune checkpoint blockade
Travel, Accommodations, Expenses - Gustave Roussy Cancer Center; Peerview
 
Carrie Daniel-MacDougall
No Relationships to Disclose
 
Jennifer McQuade
Honoraria - Bristol-Myers Squibb; Merck; Roche
Consulting or Advisory Role - Bristol Myer Squibb; Roche Pharma AG
Travel, Accommodations, Expenses - Merck